Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-27T21:54:04.880Z Has data issue: false hasContentIssue false
  • English
  • Français

Weight Gain in Epileptic Patients During Treatment with Valproic Acid: a Retrospective Study

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Weight gain has been recognized as a common adverse effect of valproic acid (VPA) that leads to discontinuation in some patients but its incidence and correlates have been rarely studied.

Methods:

We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy. Patients were divided into non-weight gainers (< 5% baseline body weight), mild-moderate weight gainers (5-10% body weight) and marked weight gainers (> 10% body weight). The following variables were statistically analyzed to determine their relationship to weight gain: gender, age, body mass index, drug dose, personal or family history of obesity and monotherapy versus polytherapy.

Results:

Seventy-one percent of the VPA group were weight gainers versus 43% in the CBZ group. A weight gain of more than 4 kg in 70% of the VPA group was observed. The weight gain was often sustained and frequently socially significant to the patients. Patients below or within normal range body mass index prior to the start of VPA experienced the most severe percentage weight gain. From the structured patient interviews, patients with no personal history of weight problems experienced the greatest initial weight increase.

Conclusion:

Strategies should be devised to help patients avoid weight gain when starting on VPA, especially if they are not already overweight.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 3 , August 1997 , pp. 240 - 244
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

REFERENCES

1.Meunier, H, Carraz, G, Meunier, V, Eymard, M. Propriètès pharmacodynamiques de l’acide n-propylacètique. Thèrapie 1963; 18: 435–438.Google Scholar
2.Mattson, RH, Cramer, JA, Collins, JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–771.CrossRefGoogle ScholarPubMed
3.Davis, R, Peters, DH, McTavish, D. Valproic acid — a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332–372.CrossRefGoogle ScholarPubMed
4.Laljee, HCK, Parsonage, MJ. Unwanted effects of sodium valproate in the treatment of adult patients with epilepsy. In: Parsonage, MJ, Caldwell, ADS, eds. The Place of Sodium Valproate in the Treatment of Epilepsy: Royal Society of Medicine International Congress and Symposium No. 30. London: Academic Press Inc and the Royal Society of Medicine, 1980: 141–158.Google Scholar
5.Davidson, DLW. The adult EPITEG trial: a comparative multicentre clinical trial of sodium valproate and carbamazepine in adult onset epilepsy. Part 2: adverse effects. In: Chadwick, DW, ed. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy, International Congress and Symposium Series No. 152. London: Royal Society of Medicine Services, 1989: 114–121.Google Scholar
6.Spitz, MC, Deasy, DN. Conversion to valproate monotherapy in nonretarded adults with primary generalized tonic-clonic seizures. J Epilepsy 1991; 4: 33–38.Google Scholar
7.Pijl, H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mech Management. Drug Safety 1996; 14: 329–342.CrossRefGoogle ScholarPubMed
8.Dam, M, Gram, L. Weight changes in epileptic patients treated with valproate. In: Pedersen, B, Orum, H, eds. Valproate in the Treatment of Seizures: meeting of the Danish Epilepsy Society. Copenhagen: Danish Epilepsy Society, 1981: 83–85.Google Scholar
9.Dinesen, H, Gram, L, Andersen, , Dam, M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 69: 65–69.Google Scholar
10.Ananth, J, Van Den Steen, N. Clobazam in the treatment of anxiety neurosis: a double-blind study. Curr Ther Res 1979; 26: 119–126.Google Scholar
11.Reader, BA, Angel, A, Ledoux, M, et al. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Can Med Assoc J 1992; 146 (11): 2009–2019.Google Scholar
12.Canadian Guidelines for Healthy Weights: promoting healthy weights (discussion paper), Health and Welfare Canada, Health Services and Promotion Branch, Ottawa, 1988.Google Scholar
13.Price, DJE. The advantages of sodium valproate in neurosurgical practice. In: Legg HJ, ed. Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy. Kent, England: MCS Consultants, 1975: 44–49.Google Scholar
14.Clark, JE, Covanis, A, Gupta, AK, Jeavons, PM. Unwanted effects of sodium valproate in children and adolescents. In: Parsonage, MJ, Caldwell, ADS, eds. The Place of Sodium Valproate in the Treatment of Epilepsy: Royal Society of Medicine International Congress and Symposium No. 30. London: Academic Press Inc and the Royal Society of Medicine, 1980: 133–139.Google Scholar
15.Richens, A, Davidson, DLW, Cartlidge, NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–687.Google Scholar
16.Isojarvi, JIT, Laatikainen, TJ, Knip, M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–584.Google Scholar
17.Breum, L, Astrup, A, Gram, L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666–670.CrossRefGoogle ScholarPubMed
18.Egger, J, Brett, EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J 1981; 283: 577–580.Google Scholar
19.Vorum, H, Gram, L, Honoré, B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res 1993; 16: 55–64.CrossRefGoogle ScholarPubMed